ClinicalTrials.gg
CompletedNCT01420055GRACEUpdated Nov 18, 2016

Fingolimod -Response According to Coping - Evaluation

A Phase 4 interventional study of fingolimod in Multiple Sclerosis, Relapsing-Remitting, sponsored by Novartis Pharmaceuticals. Completed at 47 sites in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
189
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
8th of 19
189 · median 142
Started
2011
with 5 others
Phase 4
14 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 8th largest by enrollment, is one of 6 that started in 2011, is one of 14 in phase 4, and was the 6th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

This is a prospective, open-label, multi-center phase IV study to assess response to fingolimod initiation according to coping profile in adult patients with highly active relapsing remitting multiple sclerosis in France.

03

Conditions studied

  • Multiple Sclerosis, Relapsing-Remitting

Keywords

  • Multiple sclerosis
  • Fingolimod
  • Coping
  • Anxiety
  • France
  • Treatment Satisfaction Questionnaire for Medication-9 items (TSQM 9)
  • Active
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 year-old male \& female with RRMS (2005 revised McDonald criteria) corresponding to fingolimod indication (in Europe) and EDSS score 0 - 5.5 inclusive

Exclusion criteria

Exclusion Criteria:

  • History of immune system chronic disease other than MS or known immunodeficiency syndrome; increased risk for opportunistic infections, including patients; severe active infections, active chronic infections; negative for varicella-zoster virus IgG antibodies; live or ;
  • Active ; Macular edema; Cardiac disease or medicines decreasing heart rate; severe liver impairment; lymphocyte count \<800/mm3;
  • Pregnant or nursing (lactating) women / UNLESS they are using an effective method;
  • ; participation in any clinical research study within 6 months prior to baseline; prior participation in a trial with fingolimod

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    fingolimod

    Drug: fingolimod

Interventions

06

What researchers measure

Primary outcomes

  1. To assess the mean change in Hospital Anxiety Depression Scale (HADS) anxiety sub-score between baseline and Month 4 in RRMS fingolimod treated patient total population, and according to coping profile (task, emotion or avoidance oriented).

    Time frame: 4 months

Secondary outcomes

  1. To assess patient Clinical Global Impression (CGI) and clinician CGI at M4 in total population, and according to coping profile.

    Time frame: 4 months

  2. To evaluate the safety and tolerability of fingolimod 0.5 mg/day (especially initial cardiac effects, liver function and macular edema onset)

    Time frame: 4 months

  3. To explore treatment satisfaction with fingolimod in patients with RRMS either naive (rapidly evolving severe RRMS) or who transitioned from previous treatment with Disease Modifying Therapy using the TSQM 9 and according to coping profile

    Time frame: 4 months

07

Study locations

47 sites
  • Novartis Investigative Site
    Agen Cedex 9, 47923, France
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Auxerre, 89000, France
  • Novartis Investigative Site
    Avignon, 84000, France
  • Novartis Investigative Site
    Bayonne, 64109, France
  • Novartis Investigative Site
    Beziers, 34525, France
  • Novartis Investigative Site
    Bobigny Cedex, 93009, France
  • Novartis Investigative Site
    Brest, 29240, France
  • Novartis Investigative Site
    Calais, 62107, France
  • Novartis Investigative Site
    Castelnau-le-Lez, 34170, France
  • Novartis Investigative Site
    Chambray les Tours, 37175, France
  • Novartis Investigative Site
    Cherbourg, 50100, France
  • Novartis Investigative Site
    Clermont-Ferrand Cedex 1, 63003, France
  • Novartis Investigative Site
    Créteil, 94010, France
  • Novartis Investigative Site
    Dijon, 21034, France
  • Novartis Investigative Site
    Epinal, 88021, France
  • Novartis Investigative Site
    Grenoble Cedex 9, 38042, France
  • Novartis Investigative Site
    Hagueneau, 67500, France
  • Novartis Investigative Site
    La Rochelle cedex 1, 17019, France
  • Novartis Investigative Site
    La Seyne sur mer, 83500, France
  • Novartis Investigative Site
    Le Kremlin Bicetre, 94275, France
  • Novartis Investigative Site
    Le Mans Cedex 09, 72037, France
  • Novartis Investigative Site
    Limoges, France
  • Novartis Investigative Site
    Lyon, 69275, France
  • Novartis Investigative Site
    Marseille, 13008, France
  • Novartis Investigative Site
    Marseille, 13012, France
  • Novartis Investigative Site
    Metz, 57085, France
  • Novartis Investigative Site
    Montpellier, 34000, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Nimes, 32900, France
  • Novartis Investigative Site
    Orsay, 91401, France
  • Novartis Investigative Site
    Paris, 75005, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Pontoise, F-95300, France
  • Novartis Investigative Site
    Reims, 51092, France
  • Novartis Investigative Site
    Rennes Cedex, 35033, France
  • Novartis Investigative Site
    Roanne, 42328, France
  • Novartis Investigative Site
    Saint Aubin sur Scie, 76550, France
  • Novartis Investigative Site
    Saint Jean, 31243, France
  • Novartis Investigative Site
    Sainte Foy les Lyon, 69110, France
  • Novartis Investigative Site
    Saumur, 49400, France
  • Novartis Investigative Site
    Strasbourg Cedex, 67091, France
  • Novartis Investigative Site
    Talant, 21240, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Tourcoing, 59200, France
  • Novartis Investigative Site
    Tours Cedex, 37044, France
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2011
First posted
Aug 19, 2011
Start
Aug 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01420055
Responsible party
Sponsor
First posted
Aug 19, 2011
Start date
Aug 2011
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Nov 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion